IRVINE, CA--(Marketwired - Aug 17, 2017) - Cannabis Science, Inc. (
The 2017 CBIS/FSO NAC MBS001 harvest schedule has been accelerated to immediately complete harvesting the 15-acre Phase 1 immediately. The Phase 2 harvest will begin and be completed very shortly thereafter. The management group is now hiring approximately 25 additional local workers to assist in this massive endeavor, and this direct community job creation initiative is a very important part of its Native American economic development plan for our industrial hemp project on San Joaquin Sovereign Tribal Fee land MBS, California.
"The 2017 CBIS/FSO NAC MBS001 harvest is going much better than expected, with the plants growing very fast," stated Cannabis Science CEO and CO-Founder, Mr. Raymond C. Dabney. "Many are over 6 feet tall and 5 feet wide right now. They were all planted about ten feet apart and now they are beginning to grow into each other and are nearing peak growth. This is a good problem to have when your plants are over 5 to 6 feet tall and over 5 feet wide and there are literally rows and rows of trees growing in sync with the branches so heavy at the bottom they are beginning to break off. Some of the larger branches are beginning to touch the ground leading to the accelerated harvest schedule.
"The timing of harvest is very important because at this point of the growth cycle we can maximize production and extraction usage profiles. We are bringing in extra equipment and arranging additional secure storage space to handle this large amount of raw product. The additional equipment needed for extraction of industrial and medicinal oils and fibrous products of this Hemp crop is being acquired now and some of the on-site equipment is being retrofitted now for such a mass production on the site, this will enable a much larger processing ability to start immediately.
"The 2017 CBIS/FSO NAC MBS001 harvest is still expected to yield approximately 70,000-pounds of raw inventory with wholesale numbers around $500.00 per lb. Again, there is a possible high demand for quantity and high quality profiles that can create a considerable increase in value for the initiative. The Native American initiative is certainly one of our key projects and now is the time that loyal shareholders have been waiting for. This is another key indicator that our growth schedule is on track and our success is at hand," stated Cannabis Science CEO and CO-Founder, Mr. Raymond C. Dabney.
About Cannabis Science, Inc. Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
Cannabis Science, Inc. Dr. Allen Herman Chief Medical Officer (CMO) allen.herman@cannabisscience.com Tel: 1-888-263-0832 Cannabis Science, Inc. Mr. Raymond C. Dabney President & CEO, Co-Founder raymond.dabney@cannabisscience.com Tel: 1-888-263-0832
